Global Biosimilars Market size: NA vs Europe Comparison (2024–2032)

The global biosimilars landscape demonstrated strong regional progression, with North America and Europe remaining the two most influential markets through ***. North America was valued at USD ***.*** million in *** and is projected to reach USD ***.*** million by ***, driven by expanding biosimilar approvals, robust commercialization pathways, and increasing uptake across oncology, autoimmune, and chronic disease therapies. Europe was valued at USD ***.*** million in *** and is projected to grow to USD ***.*** million by ***, supported by strong regulatory harmonization, widespread clinical adoption, and active tender-based procurement systems. While North America maintains the largest market position, Europe’s sustained growth reflects deeper clinical integration and competitive pricing frameworks. Together, these two regions continue to anchor global biosimilars expansion through rising demand and policy-driven market modernization.